



ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: www.americasblood.org

2020 #16

May 1, 2020

INSIDE:

RESEARCH IN BRIEF ...	3
REGULATORY NEWS...	4
WORD IN WASHINGTON	4
MEMBER NEWS.....	4
GLOBAL NEWS.....	5
May SMT Journal Club Webinar Articles Announced.....	6
ADRP Webinar: COVID-19 Pandemic Forum - Retention of New & Lapsed Donors During and After Pandemic.....	6
COMPANY NEWS.....	7
Upcoming ABC Webinars - Don't Miss Out!.....	7
CALENDAR.....	8
POSITIONS.....	8

ABC COVID-19 Advocacy Outreach & Updates

HHS Letter. This week, America's Blood Centers (ABC) joined AABB in sending a joint [letter](#) to U.S. Health and Human Services Secretary Alex Azar asking the agency to include and prioritize funding for blood centers as they continue to respond to the COVID-19 pandemic. "To protect the infrastructure of the nation's blood supply, we urge the U.S. Department of Health and Human Services (HHS) to ensure COVID-19 resources appropriated by Congress are promptly allocated to not-for-profit blood centers...The CARES Act recognized the impact of COVID-19 on blood centers and directed funding towards "addressing the blood supply chain" as part of the Public Health and Social Services Emergency Fund. To date, no relief has been allocated to blood centers either through the emergency fund or as part of hospital relief provisions. With blood centers facing negative to break-even operating margins before this pandemic, they cannot afford to wait any longer for necessary relief." The letter also notes the operational and logistical challenges that COVID-19 has caused for blood centers including:

- implementing social distancing into policies and procedures;
- the cancellation of "tens of thousands of blood drives;"
- "increased infection control procedures;" and
- "acquisition of personal protection equipment."

The organizations also described the implications of decreased elective surgeries and reduced blood usage for the blood community, "[d]espite the ever-present need for an available blood supply, patient utilization of blood components has decreased 30 to 40 percent on average as elective surgeries have been postponed or cancelled, with some communities experiencing far higher decreases. The result is a devastating drop in revenue for centers that is financially unsustainable. When blood usage increases again, blood centers will face additional costs to recruit new donors in addition to the increased costs of the necessary public health measures that increase costs and decreased efficiency." It concludes by asking HHS for "prompt financial action" to ensure the sustainability and availability of the nation's blood supply.

Congressional Letter. On Thursday, April 30th, nearly 50 members of Congress sent a letter to congressional leadership in support of financial relief for blood centers thanks to the outreach efforts of ABC members in contacting their members of Congress. The [letter](#) urged congressional leadership, the Speaker of the House and Minority Leader, to include assistance for not-for-profit blood centers in the next COVID-19 relief package, outlining the work of blood centers in meeting the needs

(continued on page 2)



ABC COVID-19 Advocacy Outreach & Updates (continued from page 1)

of patients during COVID-19 by maintaining a safe and robust blood supply as well as the collection of COVID-19 convalescent plasma. Reps. Jerry McNerney (D-Calif.), Eliot Engel (D-N.Y.), Rodney Davis (R-Ill.), and Brian Fitzpatrick (R-Penn.) lead the bipartisan effort and issued a news [release](#).

COVID-19 Convalescent Plasma (CCP) Blood Bulletin Published. ABC's Scientific, Medical, and Technical (SMT) Publications Committee announced the publication of the latest edition of *Blood Bulletin* in [MCN 20-050](#). This *Blood Bulletin* is entitled "COVID-19 Convalescent Plasma - a Potentially Effective Therapeutic Modality" and is intended to be an educational resource for hospitals. It describes the potentially safe and effective, but unproven therapeutic modality of CCP, while providing additional background and context regarding the application of CCP from healthcare providers to COVID-19 patients.

The article was written by Nancy Van Buren, MD, Associate Medical Director for Innovative Blood Resources, a division of New York Blood Center, Nanci Fredrich, RN, BSN, MM, Transfusion Safety and Blood Management Officer for Versiti, and Richard Gammon, MD, Medical Director for OneBlood. Contributors also included Marissa Li, MD, Medical Director for Vitalant, Louis Katz, MD, Chief Medical Officer for Mississippi Valley Regional Blood Center, and Rita Reik, MD, FCAP, Chief Medical Officer for America's Blood Centers. [PDF](#) and [MS-Word](#) versions of the publication are available on the ABC member site.

Letter to the American Hospital Association *et al.* ABC and AABB sent a joint letter to the American Hospital Association, the American College of Surgeons, the American Society of Anesthesiologists, and the Association of perioperative Registered Nurses describing the impact of hospitals resuming the elective surgeries on the blood community. It encouraged the organization to remember and include the nation's blood supply and blood providers in the "planning process to resume elective surgeries" adding that "we recognize there is a pent-up demand for elective procedures and hospitals are eager to resume normal operations, it is essential to consider the blood supply and ensure there is sufficient blood available for the rate these procedures are rescheduled. Furthermore, this consideration must include the ongoing need for blood for trauma victims and patients with cancer or other chronic diseases that require blood components. It is essential that all hospitals coordinate their blood needs with their local blood center as they begin to resume their surgical schedules. Blood conservation techniques should continue during the declared emergency and any procedures requiring large blood support should be coordinated with the local blood supplier. Resupply from other areas is available at this time through local blood suppliers, however, the time it takes to get blood around the country is longer than it has been in the past due to the lack of commercial air flights and a shift to reliance on Federal Express and United Parcel Services for transport... To ensure the blood supply continues to remain sufficient during this unprecedented time, coordination between hospitals and blood centers remains critical. We strongly urge you to relay this important information to your members and ensure the blood supply is a part of all decisions to resume elective surgeries." The complete [letter](#) is available on the ABC website.

(Source: ABC & AABB Joint [Letter](#) to HHS, 4/24/20; Congressional [Letter](#), 4/29/20; Congressional News [Release](#), 4/30/20; [MCN 20-050](#), 5/1/20; ABC & AABB Joint [Letter](#) to American Hospital Association, 4/27/20;) 💧



RESEARCH IN BRIEF

Targeting COVID-19 Convalescent Plasma (CCP) Donors. An article recently published in *Transfusion and Apheresis Science* discussed a targeted strategy of using donors who were fully recovered-COVID 19 patients as the source of antibodies in plasma collected. The authors stated that the “plasmapheresis procedure is...targeted to male donors, who consist of about 75 percent of the COVID-19 population” and who are able to undergo up to a triple plasmapheresis procedure. It was also noted that “as some of these donors have already been in an induced-hypercoagulable state and prone to thrombosis and deep venous thrombosis (DVT) that this strategy will be partially aimed at improving their health with the use of citrate-based anticoagulants and removal of high molecular weight viscous components which contribute to the untoward clinical effects of DVT.” The paper also stated that “extensive community testing for antibody will be required to find recovered patients who will volunteer to help others by donating plasma.” It was emphasized that “such a therapeutic intervention can be considered as a true reflection of the precision transfusion concept, consisting of the use of the right product for the right patient in the right time and the right condition, with no risk but added health benefits to donors and recipients alike.” Several key points of total quality management need to be addressed and include:

- retention of blood specimens to permit retrospective determination of the characteristics of an effective product and dosage regimen, as well as the characteristics of patients most likely to benefit from this intervention; and
- collection of CCP only by apheresis (double and triple collections if possible) in order to avoid unnecessary loss of red cells in the donor and to optimize the volume of plasma that can be generated.

Donor blood/serum/plasma samples as well as plasma aliquots are being saved and frozen at -80°C for retrospective testing and further scientific investigations in the United Kingdom. The CCP should be frozen as soon as possible at -18°C or colder for up to 12 months from collection so that it will be available to patients on demand. The authors concluded that “the suggested protocol of targeted plasmapheresis of volunteer recovered COVID-19 patients, constitutes a feasible, well-established and effective therapeutic modality for the treatment of critically ill patients with severe respiratory distress syndrome or septic shock in COVID-19 infected patients.”

Citation: Seghatchian, J., Lanza, F. [Convalescent Plasma, an Apheresis Research Project Targeting and Motivating the Fully Recovered COVID 19 Patients: A Rousing Message of Clinical Benefit To Both Donors and Recipients Alike.](#) *Transfusion and Apheresis Science*. 2020.

Contributed by Richard Gammon, MD, Medical Director at OneBlood 

The ABC Newsletter (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2020 by America's Blood Centers. Reproduction of the ABC Newsletter is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the healthcare system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers

Chief Executive Officer: Kate Fry

Chief Medical Officer: Rita Reik

Editor: Mack Benton

Subscriptions Manager: Leslie Maundy

Annual Subscription Rate: \$390

Send subscription queries to

memberservices@americasblood.org

America's Blood Centers

1717 K St. NW, Suite 900, Washington, DC 20006

Phone: (202) 393-5725

Send news tips to newsletter@americasblood.org.



REGULATORY NEWS

The U.S. Food and Drug Administration (FDA) updated the [guidance](#) entitled “Investigational COVID-19 Convalescent Plasma” on Friday, May 1st. The updated guidance recommends “[c]omplete resolution of symptoms at least 14 days before the donation,” eliminating the need for a negative COVID-19 diagnostic test to donate between 14 and 28 days after symptom resolution. Additionally, it states that “[a]lthough optional for all IND pathways, storing samples for single patient eINDs is not recommended.”

The agency also announced a newly approved variance this week “Exceptions and Alternative Procedures Approved Under 21 CFR 640.120.” The variance, 21 CFR 640.69(f), is available on the FDA [website](#) and states, “Hold Source Plasma units donated by paid donors and determined to be suitable for further manufacturing into injectable products, in quarantine for a minimum of 45 calendar days before release for further manufacturing. This alternative procedure is intended to remain in effect only for the duration of the public health emergency related to COVID-19 declared by the Department of Health and Human Services, including any renewals made by the Secretary in accordance with section 319(a)(2) of the PHS Act, or until FDA provides further notification.”

(Sources: FDA [Guidance](#) Update, 5/1/20; FDA [Announcement](#), 4/28/20) ◆

WORD IN WASHINGTON

Two members of Congress who tested positive for COVID-19 and have since completely recovered donated COVID-19 convalescent plasma (CCP) at two ABC member blood centers this week. Congressman Mario Diaz-Balart (R-Fla.) made a CCP donation to OneBlood [according](#) to *The Hill*. “I’m extremely grateful to, not only have completely recovered from COVID-19, but also to have been able to donate my plasma to help those with serious or immediately life-threatening coronavirus infections,” said Rep. Diaz-Balart to *The Hill*. “I strongly encourage people who have recovered from COVID-19 to become a donor, it could save someone’s life. I thank the OneBlood team for their amazing work. During a time of crisis, it’s crucial that we come together to help any way we can.” Rep. Joe Cunningham (D-S.C.) also [donated](#) CCP at The Blood Connection, Inc. this week following his recovery from COVID-19. “I think now is the time in our district, our state and our country, where everybody needs to be doing whatever they can to help out our neighbors,” said Rep. Cunningham to WCBD NBC News-2.

(Source: *The Hill*, [First member of Congress diagnosed with COVID-19 donating blood for treatment](#), 4/30/20; [WCBD NBC News-2, Rep. Cunningham donates plasma for COVID-19 recovery efforts](#), 4/30/20)



MEMBER NEWS

A COVID-19 convalescent plasma (CCP) donor at **South Texas Blood & Tissue Center** recently had the opportunity to “virtually” meet a recipient of his convalescent plasma donation. David Herrmann, now recovered from COVID-19, was able to successfully donate CCP at South Texas Blood & Tissue Center, “I felt it was the right thing to do to help my community,” he [told](#) ABC KSAT-12. His donation was used as part of the treatment for Jimmie Hayden, who was hospitalized as he battled COVID-19. Two days following the CCP treatment, Mr. Hayden began making “significant progress” according to ABC KSAT-12. “[Mr. Herrmann] is my hero and someone who I definitely hold dear to my heart, and again I can’t thank him enough.” Mr. Hayden continues to recover at home now and plans to become a CCP donor moving forward. “That’s the best way I know to help someone is to pay it forward and do what [Mr. Herrmann] did.”

(Source: ABC KSAT-12, [San Antonio COVID-19 patient meets plasma donor he says saved his life](#), 4/29/20)

(continued on page 5)

MEMBER NEWS (continued from page 4)

Héma-Québec and Canadian Blood Services are receiving \$1 million worth of advertising time from Toyota Canada to assist the organizations in communicating the ongoing need for blood and blood products during the COVID-19 pandemic. “Many Canadians are looking for a way to help their community during this pandemic and donating blood is one way they can make an important difference,” [said](#) Stephen Beatty, vice president of Corporate at Toyota Canada Inc. to Motors Actu. “Our partners at Canadian Blood Services and Héma-Québec suggested that, along with our dealers across Canada, we could do our part by spreading the message that blood will continue to be necessary to help patients in Canada in the months ahead. One powerful choice people can make is to book an appointment to donate blood or register online to become a stem cell or organ donor.”

(Source: Motors Actu, [Toyota Canada and its dealers expand their partnership with Canadian Blood Services and Héma-Québec during COVID-19 pandemic](#), 4/14/20) ♦

GLOBAL NEWS

Northern Ireland is [revising](#) its blood donor eligibility requirements for men who have sex with other men (MSM) to three months. According to *BBC News*, the change will begin on June 1st as the previous deferral period had been 12 months. Northern Ireland Minister of Health Robin Swann told the news organization that the decision was made based on “evidence regarding the safety of donated blood.” He added, “Any one of us may require a blood transfusion in the future and we need to be confident that the blood we receive is safe...Not even the most advanced tests are 100 percent reliable, so it is vitally important for every donor to comply with any deferral rules that apply to them.” The revised policy aligns Northern Ireland with the United Kingdom who implemented a three-month MSM deferral policy in 2017.

(Source: *BBC News*, [Northern Ireland blood donation rules relaxed for gay and bisexual men](#), 4/29/20)

The European Medicines Agency’s (EMA) Committee for Advanced Therapies [issued](#) a warning to public and patients regarding the use of unregulated cell-based therapies. The organization noted that such unregulated therapies can harm individuals leading to complications and adverse side effects or outcomes, “Patients using unproven or unregulated cell-based therapies have reportedly suffered serious, sometimes fatal, side effects including infections, unwanted immune reactions, [tumor] formation, loss of vision and bleeding in the brain. Cell-based therapies are treatments using cells from the patient or a donor. The use of blood and cells for transplantation is a well-established medical practice. However, if cells are not used for the same essential function in the recipient as in the donor or if they are being substantially manipulated, they are not considered transplants and their safety and benefits cannot be assumed. For this reason, such therapies are regulated in the EU as medicinal products. The concerns echo those from the U.S. Food and Drug Administration (FDA) who issued a similar warning last year to consumers and patients, stating that the agency, “is concerned that some patients seeking cures and remedies are vulnerable to stem cell treatments that are illegal and potentially harmful. And the FDA is increasing its oversight and enforcement to protect people from dishonest and unscrupulous stem cell clinics, while continuing to encourage innovation so that the medical industry can properly harness the potential of stem cell products. To do your part to stay safe, make sure that any stem cell treatment you are considering is either:

- FDA-approved or;
- being studied under an Investigational New Drug Application (IND), which is a clinical investigation plan submitted and allowed to proceed by the FDA.”

(Sources: EMA [Announcement](#), 4/28/20; FDA [Announcement](#), 9/3/19) ♦



America's Blood Centers®
It's About *Life.*

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.

May SMT Journal Club Webinar Articles Announced

The ABC Scientific, Medical, and Technical (SMT) Journal Club Webinar on May 4th at 3p.m. EDT will feature the articles below:

- [The impact of patient blood management on blood utilization and clinical outcomes in complex spine surgery](#) (*Transfusion*);
- [How do I incorporate red cell genotyping to improve chronic transfusion therapy?](#) (*Transfusion*); and
- [Cold-stored whole blood: A better method of trauma resuscitation?](#) (*Journal of Trauma and Acute Care Surgery*).

Additional details including registration are available to ABC members within [MCN 20-047](#).

(Source: ABC Webinar [Announcement](#), 4/22/20)

ADRP Webinar: COVID-19 Pandemic Forum - Retention of New & Lapsed Donors During and After Pandemic

[Register](#) today for the Wednesday, May 6th ADRP Webinar entitled “COVID-19 Pandemic Forum - Retention of New and Lapsed Donors During and After Pandemic.” This webinar will take place at 1 p.m. EDT and will feature a panel discussion of strategies to use for engaging and retaining blood donors that have responded to outreach efforts. The panelists include Theresa Pina, vice president of Operations at Gulf Coast Regional Blood Center, Amanda Farrell, director of Donor Recruitment for ConnectLife, and Amanda Hess, director Donor and Public Relations for Mississippi Valley Regional Blood Center. ADRP subscribers may register for free and non-subscribers can participate for \$25.

(ADRP [Announcement](#),4/16/20) ♦

ABC Calendar of Events

ABC offers a variety of meetings, workshops and virtual opportunities for education and networking as well as participation in ABC business. The [calendar of events](#) includes annual and summer meetings, board meetings, workshops, and webinars, and details will be updated as confirmed. We look forward to your support and participation!

RESEARCH BRIEFS

America's Blood Centers welcomes contributions or briefs from guest authors for scientific/medical peer-reviewed published papers. The views/comments expressed in submitted articles from external parties are those of the author(s) and are not to be interpreted as the viewpoint of America's Blood Centers. If you are interested in contributing a brief for potential publication please contact us [here](#).



COMPANY NEWS

Ortho Clinical Diagnostics has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for a second COVID-19 antibody test. According to an April 25th news [release](#), the test has “demonstrated 100 percent specificity” as was the case with its earlier total antibody test previously. “The observed 100 percent specificity with Ortho’s VITROS SARS-CoV-2 tests allows an extremely high level of confidence so that people will not be identified as having an immune response to the virus when in fact they do not,” said New York Blood Center President and CEO Christopher D. Hillyer, MD, in the news release. “Statistically, the chance of error rises dramatically even with a very small decline from 100 percent in specificity, given our understanding of the prevalence of the COVID-19 virus today.” Vitalant Research Institute Director Michael P. Busch, MD, PhD also added in the release, “COVID-19 is a novel virus and is being both researched and treated in real-time. One of the main areas of research is identifying the time and level certain antibodies appear in the blood, which can help confirm whether a patient has been infected and whether or not they have developed antibodies. Ortho’s tests, which can detect both IgG and total antibodies, will help further our understanding of both infection and immunity to facilitate proper clinical guidance.”

(Source: Ortho Clinical Diagnostics News [Release](#), 4/25/20)

Abbott [announced](#) that it has developed lab-based serology antibody test for COVID-19. “We continue to contribute in a significant and meaningful way by providing new solutions across our diagnostics testing platforms,” said Abbott President and Chief Executive Officer Robert B. Ford in a news release. “I’m extremely proud of the many Abbott people who are working around the clock to get as many tests as we can to healthcare workers and patients.” The latest test is the company’s third COVID-19 test.

(Source: Abbott News [Release](#), 4/15/20) ◆

Upcoming ABC Webinars – Don’t Miss Out!

- **ABC SMT Journal Club Webinar** – May 4th from 3 – 4:30 p.m. (EDT). Additional details [here](#).
- **ADRP New & Lapsed Donors During & After a Pandemic**– May 6th from 1 – 2:00 p.m. (EDT). Register [here](#).

Canceled Meetings

May 5. U.S. Food and Drug Administration Medical Device User Fee Amendments for FY 2023-27 Public Meeting, Silver Spring, Md. More details [here](#).

May 12-13. AABB and Mayo Clinic Laboratories Transfuse 2020, Rochester, Minn. More details available [here](#).

May 13-14. IPFA/PEI 27th International Workshop on “Surveillance and Screening of Blood-Borne Pathogens, Porto, Portugal. More details available [here](#).



CALENDAR

Note to subscribers: Submissions for a free listing in this calendar (published in the last issue of each month) are welcome. Send information to newsletter@americasblood.org or by fax to (202) 899-2621. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)

2020

May 8. **U.S. Food and Drug Administration (FDA) Cellular, Tissue and Gene Therapies Advisory Committee Meeting, Teleconference.** More details available [here](#).

Aug. 28-29. **64th Annual California Blood Bank Society Annual Meeting, Santa Clara, Calif.** More details available [here](#).

Sept. 9. **10th Annual Symposium Red Cell Genotyping 2020: Visionary Solutions, Bethesda, Md.** More details available [here](#).

Sept. 10. **39th Annual Immunohematology and Blood Transfusion Symposium, Bethesda, Md.** More details available [here](#).

Sept. 23-25. **4th European Conference on Donor Health and Management, Hamburg, Germany.** More details available [here](#).

Oct. 3-6. **2020 AABB Annual Meeting, Baltimore, Md.** More information available [here](#).

Nov. 22-24. **2020 ADRP Conference, Phoenix, Ariz.** More details available [here](#). 💧

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for *ABC Newsletter* subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Regional Operations Director (Baton Rouge, LA). LifeShare Blood Center is seeking an enthusiastic Operations Director to oversee regional blood collection and donor recruitment operations. Responsibilities include: develop and implement strategic and tactical plans for operations within the donation center and community-based activities; direct, develop and coach teams for achievement of established goals and KPI's; develop relationships with community leaders and groups to promote our mission and business needs; ensure operations adhere to standards and regulations governing the blood banking industry, including FDA, AABB, cGMP, and OSHA; and model LifeShare's mission and values, integrating them into daily decisions, behaviors and actions. The ideal candidate has a bachelor's degree or equivalent experience and background in healthcare administration, business or operations management, including supervisory experience in the direction and coaching of other employees. S/he champions teamwork, communication and continuous improvement and has a passion for service to our community. Come be a part of the LifeShare team, "connecting donors and the lives they impact!"

LifeShare offers a competitive salary, incentive bonus opportunities and a generous benefits package, including employer-paid medical, life and disability insurance; 401k with employer contributions and PTO. Click [here](#) to apply.

Blood Collections Director of Quality/Projects. Kentucky Blood Center seeks a detail-oriented professional to lead a team focused on Blood Collections quality initiatives, and to facilitate the management and implementation of special projects. Supervises the Donor/Patient Services Nurse and related processes, and reports to the Vice President, Donor Services. Responsibilities include department planning, budgeting, employee supervision and development, quality oversight. Provides technical assistance for automated Blood Collections procedures (apheresis platelets/plasma/red cells, double red cells), and special programs. Primary contact and lead for the Dendreon collection program. Guides inter-departmental collaboration fulfilling responsibilities, process improvement plans, and finding

(continued on page 9)

POSITIONS (continued from page 8)

solutions. Oversees regulatory compliance, error management reporting, and procedural review and revision. Qualifications: BSN, and an active RN license required. Experience with good manufacturing practices, FDA, EU, and other regulated experience preferred. Experience with quality assurance, data analysis, and equipment/process validation highly desired. MSOffice proficiency; ability to effectively navigate other systems and web-based applications. Minimum two years of management experience required. Must be highly organized, reliable, and have outstanding interpersonal skills. Strong written and oral communication skills, solid work ethic, and a team player attitude are required. Qualified candidates must live in, or be willing to locate to, the Lexington, KY area. Click [here](#) to apply.

Clinical Laboratory Scientist. Located in the heart of the magnificent coastal redwoods of Northern California, The Northern California Community Blood Bank is a nonprofit blood bank serving Humboldt and Del Norte Counties. The Northern California Community Blood Bank has an immediate opening for a Clinical Laboratory Scientist. Both part-time and full-time, fully benefitted positions are available. The Northern California Community Blood Bank offers a low-stress environment, excellent work-life balance, and the opportunity to advance your professional development while working for an employer with a vibrant community relationship. The Clinical Laboratory Scientist is responsible for activities related to processing, testing, storage, transportation, and other handling of blood and blood products. The Clinical Laboratory Scientist performs reference immunohematological testing and participates in training, validation, implementation of new procedures, and compliance with regulatory and standard-setting agencies. Experience, Education and Licensure: Four-year degree from an accredited college or university in science, medical technology or a related field. Valid current CA license as a Clinical Laboratory Scientist. Experience preferred but will train a motivated new CLS. To apply, contact: Kristina Kelone, Technical Director, Northern California Community Blood Bank, 2524 Harrison Avenue, Eureka, CA 95501, (707) 443-8004.

Hematologist/Medical Director. OneBlood is expanding its clinical practice offerings in the areas of outpatient transfusion medicine, therapeutic apheresis & phlebotomy, pre-op anemia management, cell therapy, treatment of blood disorders. If you have a passion to join a team that is providing cutting-edge medical expertise in the areas of blood banking/transfusion medicine, hematology and outpatient clinical services, IRL, therapeutic apheresis, cellular therapy, research, consider joining our medical team as a regional **Medical Director**. This position includes a highly competitive salary, benefits package, including the option of free medical coverage,

retirement plan with company contribution PLUS a company match, company vehicle lease/allowance, paid holidays, etc. The position is based out of the Ft. Lauderdale, Florida area. Qualified candidates should possess minimum of 3 years' experience, M.D. or D.O. degree with board certification in Internal Medicine/Hematology and sub-specialty board certification in Blood Banking/Transfusion Medicine by a Board Registry recognized by the American Board of Medical Specialties. Appropriate state licenses will be required as needed. Candidates must meet the eligibility requirements to obtain appointments at hospitals served by OneBlood. For more detailed information, visit OneBlood's **Careers** page at www.oneblood.org. OneBlood, Inc., a proven leader in blood banking, is an Equal Opportunity Employer/Vet/Disability.

Director, Regulatory Affairs. America's Blood Centers (ABC), North America's largest network of community-based, independent blood programs, is seeking a Director, Regulatory Affairs. The position will be actively involved and accountable for the development, implementation, execution and advancement of the ABC regulatory agenda before federal agencies and other stakeholders. In addition, the position will assist in the facilitation of member education, evaluation and coalescing of member input in the development of industry positions, data collection from internal and external sources, and primary and secondary research. The position will report directly to the Senior Director, Federal Government Affairs, providing strategic guidance on regulatory affairs and public policy issues pertaining to the nation's blood supply. A bachelor's degree is required for the position, which is based in Washington, D.C. This individual should: have a thorough understanding of the federal regulatory processes and landscape, particularly with the FDA; have knowledge of and experience in health policy; blood industry knowledge preferably (but not required); be able to collect, analyze, and synthesize information from varied sources; have strong critical thinking, analytical, and problem-solving skills; be self-motivated and goal oriented; have the ability to multitask and determine priorities; be able to network and collaborate effectively with colleagues and volunteers; have strong communication skills - verbal, written, and presentation; and be able to travel, sometimes at short notice. ABC offers a salary commensurate with experience as well as an excellent benefit package including medical, dental, LTD, and 401k contribution. We are a hybrid virtual office that promotes a flexible work environment. This is a full-time staff position including benefits and a stipend for internet and telephone services. ABC prohibits discrimination and provides equal employment opportunities to all employees and applicants for employment without regard to race, color, religion, age, sex,

(continued on page 10)



POSITIONS (continued from page 9)

national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state or local laws. The full job description is available [here](#). Interested applicants should send a cover letter and resume to careers@americasblood.org. 💧